Perspective
Author Details :
Volume : 9, Issue : 3, Year : 2024
Article Page : 117-118
https://doi.org/10.18231/j.ijirm.2024.024
Abstract
India is having a high burden of drug-resistant tuberculosis. In a country with overwhelmed health facilities, it is a challenging task to address issues related to tuberculosis elimination. Further, India aims to achieve the global target of tuberculosis elimination by 2025, which is five years earlier than the global target. To achieve this uphill target, there is a constant need to improve the management of tuberculosis. One such latest development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against multidrug-resistant tuberculosis. The present article sheds light on this new treatment rolled out by the Government of India.
Keywords: MDR/RR-TB, DR-TB, Treatment guidelines, Shorter regimen, Longer regimens
How to cite : Yadav S, Jeyaraman N, Jeyaraman M, Rawal G, BPaLM regimen in India: A remarkable step towards tuberculosis elimination. IP Indian J Immunol Respir Med 2024;9(3):117-118
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Received : 01-08-2024
Accepted : 04-09-2024
Viewed: 214
PDF Downloaded: 36